Group items tagged

If you have recently been diagnosed with hearing loss, you may be feeling overwhelmed and unsure of what to do next. You are not alone - millions of people around the world are living with hearing loss. The good news is that there are many resources available to help you learn how to manage your condition and live a full life. In this blog post, we will discuss some of the most common issues that people with hearing loss face and provide tips on how to handle them. HANDLING ISSUES FROM HEARING LOSS - HOW TO DO IT PROPERLY Hearing loss is certainly a difficult obstacle to face in life, but it doesn't have to stop you from living a full and rich life. Of course, hearing loss comes with its own set of unique challenges, but there are ways to manage them. From learning what hearing aids are the best for you to communicate with loved ones, to the different types of therapies available, we're here to help you find the answers you need. Generally speaking, there are four main issues that people with hearing loss face; Isolation, communication difficulties, feeling overwhelmed and frustrated, and depression. Unfortunately, each of these "consequences" will likely get worse if hearing loss is not managed early on. Here are some tips on how to handle each one:

Medical professionals often prescribe semaglutide to patients who have type 2 diabetes. Along with a balanced diet and regular exercise, it has also shown to be an incredibly efficient weight loss aid for patients. As the active ingredient in well-known brand-name drugs such as Wegovy, Ozempic, and Rybelsus, semaglutide is currently on everybody's lips. But what exactly is semaglutide? Does it really work for weight loss? We'll find an answer for you in this article, and explain the main benefits of using semaglutide for weight loss. What Is Semaglutide? A number of diabetic and weight loss medications, including Wegovy, Ozempic, and Rybelsus, have semaglutide as their active ingredient. This substance is a synthetic form of the hormone glucagon-like peptide-1 (GLP-1), that occurs naturally. Developed by the company Novo Nordisk, semaglutide was first approved by the FDA in 2017 as an injection for the treatment of adult type 2 diabetes (as part of the approval procedure for Ozempic). In 2019, the Food and Drug Administration approved a novel semaglutide form known as Rybelsus. Rybelsus was the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes in the United States.

The National Pharmacy Association (NPA), representing independent community pharmacies, has called for tougher regulation of the online sale of weight loss jabs to protect patients amid a prediction of a new year's boom in demand. The association argues that current regulation "leaves the door open for medicines to be supplied without appropriate patient consultation and access to patient records." It has urged the General Pharmaceutical Council (GPhC) to require greater consultation with patients before dispensing weight loss jabs and other high-risk medication online. The association stressed that online sellers should not just rely on information provided in online questionnaires but also gather important historical medical information before a full two-way consultation between prescriber and patient. Draft guidelines on weight loss medication The GPhC proposed changes to their current guidance for online pharmacies to improve patient safety. It launched a consultation on the revised guidance on 17 September, inviting feedback until 9 October 2024 from the public, carers, pharmacists, pharmacy technicians, other healthcare professionals, and pharmacy owners. In its response to proposed guidelines on prescribing weight loss medication, the NPA highlighted critical gaps, stating that proposed safeguards "still leaves the door open for medicines to be prescribed/supplied without appropriate two-way direct patient consultation and access to patient records for a full clinical picture particularly where high-risk medicines are involved, and the risk to patient safety remains".

Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market. In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks. Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing. The enormous demand for weight-loss treatments such as Novo Nordisk's Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.

Rowlands pharmacy has launched a new weight management service across its UK network, challenging perceptions around weight loss and providing expert support to those in need. The launch comprises a pilot roll-out across 100 Rowlands branches to increase consideration of pharmacies for weight management-based advice. Commenting on the launch, Nigel Swift, managing director of Rowlands, said: "One of the biggest challenges facing many adults looking to address any weight concerns is knowing where and how to start. Our new weight management service is designed to help all those setting out on a new weight loss journey but also those who have struggled to find a plan that works for them." "Our pharmacy teams offer comprehensive healthcare advice and a variety of weight management products with a friendly approach that naturally puts customers at ease, and we're looking forward to welcoming all those looking to take their first step with us."

British pharmacies and slimming clinics are reducing prices for weight-loss drugs Wegovy and Mounjaro in a competitive bid to win patients. Both Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (Tirzepatide) injection drugs are cleared for weight loss in combination with a reduced-calorie diet and increased physical activity. Wegovy was launched in the UK market in September, with Mounjaro following in February. Initially designed for treating type 2 diabetes, the drugs have been found to also induce weight loss by suppressing appetite and decelerating digestion. As reported by Reuters, Simple Online Pharmacy has further reduced the price of starter doses of Mounjaro to £149 for a one-month supply. In February, the price was cut to £159 ($198) from £179. Additionally, the pharmacy on Monday discounted the higher Mounjaro strengths that patients take later.

A comprehensive cohort study has shed light on the benefits and risks associated with weight-loss drugs, offering valuable insights for clinical care and future research. Published in Nature Medicine on 20 January 2024, the study found the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs)-used to treat diabetes and obesity-associated with a reduced risk of substance use disorders (including alcohol, cannabis, opioid and stimulant use disorders). Weight-loss drug use was also linked to decreased risks of psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. However, the use of GLP-1RAs was not without risks, as researchers identified an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic conditions, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis associated with their use. The analysis, utilising the U.S. Department of Veterans Affairs databases, compared 215,970 GLP-1 RA users with patients using sulphonylureas (n=159,465), DPP4 inhibitors (n=117,989), SGLT2 inhibitors (n=258,614), or a composite of the three (n=536,068).

As we grow old we suffer from Age Related Hearing Loss. This type of hearing loss which occurs on account of growing age is called Presbycusis. In this blog we will try to make you aware about hearing loss related to age and its treatment.

WBA, Boots parent company revealed the results for its fourth quarter of the financial year, showing three months to August 2023. The reports published on 12 October show the loss of at least $1bn following a net loss of $3.1bn on an annual basis. This marks a decrease compared to a profit of $4.3bn in the previous financial year. The loss was attributed in part to a $5.5 billion after-tax charge related to opioid claims and litigation during the period, as well as the comparison against a $2.5 billion after-tax gain from the company's investments in Village MD and Shields Health Solutions in the same period last year. Ginger Graham, WBA's Interim Chief Executive spoke about the company's performance and its dedication to their customers and patients.

New data on weight loss drugs that could compete with Novo Nordisk's Wegovy are raising expectations there will soon be more options, and possibly lower prices, in an estimated $100 billion marketplace, doctors and pharmaceutical executives say. Drugmakers are ratcheting up their research and aiming for new formulations that can be taken as pills, options to deliver higher weight loss or drugs that reduce fat while maintaining muscle. "It has really been an explosion of innovation," said Dr. Robert Gabbay, chief science officer at the American Diabetes Association (ADA), which receives funding from both Novo and Eli Lilly and Co and just concluded its annual meeting in San Diego, California. "If there are multiple (treatments) in the market, that will lead to some level of competition and greater access."

With Novo Nordisk's patent protection for liraglutide now expired, the UK is set to welcome the first wave of generic weight loss medicines. The British Generic Manufacturers Association (BGMA), the trade body for off-patent medicines, believes these generic versions could "provide could provide much-needed capacity to meet growing demand and alleviate shortages." Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is primarily used to treat type 2 diabetes and obesity. Novo Nordisk markets liraglutide under the brand names Victoza (for type 2 diabetes and Saxenda (for weight loss). In a statement released on 20 November 2024, the BGMA confirmed that "liraglutide's patent protection was no longer in force, marking the first time generic versions of diabetes and weight loss treatments can be available in the UK." The BGMA anticipates that at least four companies will obtain UK marketing authorisations for generics targeting type 2 diabetes and obesity. However, it remains uncertain how many will launch immediately.

The Medicines and Healthcare products Regulatory Agency (MHRA) has cautioned against buying weight-loss medicines without a prescription from beauty salons, unregistered pharmacy websites or social media platforms as such products could pose "serious health risks." Consumers are reminded that the only safe way to obtain genuine weight-loss medication is through a legitimate pharmacy, including licensed online pharmacies, with a prescription from a qualified healthcare professional. To combat the illegal sale of these medicines, the MHRA's Criminal Enforcement Unit is working closely with social media platforms, technology companies, the police and Border Force. Andy Morling, MHRA deputy director of Criminal Enforcement, highlighted the dangers of purchasing these medications from unverified sources: "At this time of year, with many of us thinking about shedding a little excess weight, we see people offering weight loss medicines for sale as a quick fix, without a healthcare professional's prescription, from beauty salons, websites and on social media. "These are not cosmetic treatments; they are powerful medicines that can only be legally and safely dispensed against a prescription issued by a healthcare professional."

Are you living your life in depression? If yes then there is a chance you can lose your memory. There are types, symptoms & causes of Amnesia / Memory loss

Amnesia is commonly known as memory loss. The reason of memory loss can be an emotional or physiological disorder, drugs abusement or Brian injuries. The memory loss can be temporary or permanent but mostly refers to temporary memory loss.

A diet supplemented with vitamin D can help support healthy weight loss and reduce fat percentage, a new clinical study revealed. A trial was conducted over a three-month period with 125 overweight and obese Southeastern European Caucasians with vitamin D deficiency or insufficiency. Participants were prescribed vitamin D3 3000 IU/d oral spray supplementation, or a placebo, alongside a calorie-restricted diet programme of 600 kcal less than the total energy expenditure of each individual. The report stated that the group who were prescribed vitamin D witnessed significant improvements in serum 25(OH)D level and a greater reduction in body weight, BMI, and fat percentage in all individuals within this group. The study supported by BetterYou found that with the prevalence of low vitamin D becoming a serious global health problem in all ages, even in areas with natural sun exposure throughout the year, the study shines a light on the importance of vitamin D supplementation.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

Kent and Medway prescribe the highest number of semaglutide, liraglutide and tirzepeptide - drugs that are commonly used for treating type 2 diabetes, weight loss, or both - in the UK, according to recent research by Click Pharmacy. Called GLP-1 agonists, these drugs mimic the effects of the GLP-1 hormone, which is released by the body after eating. This hormone slows digestion, stimulates insulin release, and inhibits glucagon, a hormone that raises blood sugar, making GLP-1 agonists effective treatments for diabetes and weight management. The online pharmacy's research reveals that Kent and Medway prescribed the most of these drugs in the month of June 2024, with 6,326 prescriptions. Other NHS Integrated Care Boards (ICBs) with high prescription rates included: Black Country and West Birmingham (5,019) Hampshire, Southampton, and Isle of Wight (4,960) Birmingham and Solihull (4,775) North Central London (4,528) North East London (3,557) North West London (3,498) Cambridgeshire and Peterborough (2,973) Coventry and Warwickshire (2,912) Norfolk and Waveny (2,575) Brighton and Hove topped the list for prescribing Wegovy, a weight-loss drug containing semaglutide, with 35 prescriptions made out in June alone.

A 58-year-old nurse from North Lanarkshire, Scotland, has reportedly died after taking the weight-loss drug tirzepatide, which was recently approved for use on the NHS. Susan McGowan died from multiple organ failure, septic shock and pancreatitis, with the use of the Eli Lilly drug listed as a contributing factor on her death certificate, according to the BBC. She had taken two low-dose injections of tirzepatide, known by the brand name Mounjaro, over a two-week period before her death on 4 September. Her death is thought to be the first in the U.K. officially linked to the drug. McGowan, who had worked for over 30 years as a nurse at University Hospital Monklands in Airdrie, purchased a prescription for the drug through a registered online pharmacy. A few days after her second injection, McGowen began experiencing severe stomach pains and sickness. She went to A&E at Monklands - where her colleagues tried to save her life. Within days, her kidneys failed, and she fell into a coma as her other organs began to fail.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.